These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 21236604)
1. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme. Monjazeb AM; Ayala D; Jensen C; Case LD; Bourland JD; Ellis TL; McMullen KP; Chan MD; Tatter SB; Lesser GJ; Shaw EG Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):743-8. PubMed ID: 21236604 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509 [TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592 [TBL] [Abstract][Full Text] [Related]
5. Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1). Massaccesi M; Ferro M; Cilla S; Balducci M; Deodato F; Macchia G; Valentini V; Morganti AG Int J Clin Oncol; 2013 Oct; 18(5):784-91. PubMed ID: 22892797 [TBL] [Abstract][Full Text] [Related]
6. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738 [TBL] [Abstract][Full Text] [Related]
8. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. Morganti AG; Balducci M; Salvati M; Esposito V; Romanelli P; Ferro M; Calista F; Digesù C; Macchia G; Ianiri M; Deodato F; Cilla S; Piermattei A; Valentini V; Cellini N; Cantore GP Int J Radiat Oncol Biol Phys; 2010 May; 77(1):92-7. PubMed ID: 19683876 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience. Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126 [TBL] [Abstract][Full Text] [Related]
10. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821 [TBL] [Abstract][Full Text] [Related]
11. Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. Reddy K; Gaspar LE; Kavanagh BD; Chen C J Med Imaging Radiat Oncol; 2014 Dec; 58(6):714-21. PubMed ID: 24975917 [TBL] [Abstract][Full Text] [Related]
13. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update. Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344 [TBL] [Abstract][Full Text] [Related]
14. Treatment of high-grade gliomas using escalating doses of hypofractionated simultaneous integrated boost-intensity-modulated radiation therapy in combination with temozolomide: A modified Phase I clinical trial. Ge X; Xue X; Liu H; Wang Y; Xiao Z; Tian L; Chang X; Lin Q; Yu J J Cancer Res Ther; 2018; 14(7):1482-1491. PubMed ID: 30589027 [TBL] [Abstract][Full Text] [Related]
15. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169 [TBL] [Abstract][Full Text] [Related]
16. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Sultanem K; Patrocinio H; Lambert C; Corns R; Leblanc R; Parker W; Shenouda G; Souhami L Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):247-52. PubMed ID: 14697445 [TBL] [Abstract][Full Text] [Related]
17. Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. Fuller CD; Choi M; Forthuber B; Wang SJ; Rajagiriyil N; Salter BJ; Fuss M Radiat Oncol; 2007 Jul; 2():26. PubMed ID: 17629934 [TBL] [Abstract][Full Text] [Related]
18. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience. Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151 [TBL] [Abstract][Full Text] [Related]
19. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R; Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848 [TBL] [Abstract][Full Text] [Related]
20. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]